Navigation Links
Lotus Pharmaceuticals to Present at Rodman & Renshaw Conference
Date:11/4/2008

BEIJING, Nov. 4 /Xinhua-PRNewswire-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS) ("Lotus" or the "Company"), a pharmaceutical company in the People's Republic of China ("PRC"), today announced that it will present at the upcoming Rodman & Renshaw Global Investment Conference taking place from November 10 to 12, 2008 in New York City.

The date, time and location of Lotus Pharmaceuticals' presentation at the conference are:

Date: Tuesday, November 11, 2008

Time: 12:25 P.M. EST

Venue: Henry Salon, 5th Floor

The New York Palace Hotel

455 Madison Avenue

New York, NY 10022

This three day conference will feature presentations from more than 250 companies in the healthcare, steel, metals and mining and energy industries, with an "Asia & Growth" track. The Company's Chief Financial Officer will present at the conference. For more information about the conference, please view http://www.rodmanandrenshaw.com or E-mail lk@rodmanandrenshaw.com

About Lotus Pharmaceuticals, Inc.

Lotus Pharmaceuticals, Inc. controls and operates Liangfang Pharmaceutical Company, Ltd. ("Liang Fang") and En Ze Jia Shi Pharmaceutical Company, Ltd. ("En Ze"), two pharmaceutical companies located in Beijing, China. Together, Liang Fang and En Ze form an operating company (together, "Lotus East"). Lotus East engages in the development of new drugs, drug manufacturing, and the marketing and sales of pharmaceuticals. Lotus East has advanced pharmaceutical production equipment with which it produces a portfolio of pharmaceutical products, and meets National GMP. Lotus East has a number of highly skilled scientists, 2,000 square meters of office space and a 1,000 square meter warehouse. It operates ten retail pharmacies in the Beijing area.

Safe Harbor Statement

This press release contains "forward-looking statements" within the meaning of the "safe-harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual results of the Company to differ materially from the results expressed or implied by such statements, including changes from anticipated levels of sales, future national or regional economic and competitive and regulatory conditions, changes in relationships with customers, access to capital, difficulties in developing and marketing new products, marketing existing products, customer acceptance of existing and new products, and other factors. Additional information regarding risks can be found in the Company's Annual Report on Form 10K filed with the SEC. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company has no obligation to update the forward-looking information contained in this press release.

For more information, please contact:

Lotus Pharmaceuticals, Inc.

Mr. Adam Wasserman, CFO

Phone: +1-877-801-0344

Email: info@LotusEast.com

Website: http://www.lotuseast.com

CCG Investor Relations Inc.

Mr. Crocker Coulson, President

Phone: +1-646-213-1915 (New York)

Email: crocker.coulson@ccgir.com

Website: http://www.ccgir.com


'/>"/>
SOURCE Lotus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Lotus Pharmaceuticals Announces Conference Call to Discuss Second Quarter 2008 Results
2. Lotus Pharmaceuticals, Inc. Reaffirms its Confidence in Meeting its Make Good Target for Fiscal Year 2008
3. Lotus Pharmaceuticals, Inc. Announces Conference Call to Discuss First Quarter 2008 Results
4. Lotus Pharmaceuticals, Inc. Announces Resignation of Director Mel Rothberg
5. Lotus Pharmaceuticals, Inc. Announces Fourth Quarter and Fiscal Year 2007 Results
6. Lotus Pharmaceuticals, Inc. Announces Conference Call to Discuss Fourth Quarter and Fiscal Year 2007 Results
7. Lotus Pharmaceuticals Raises $5 Million in Private Placement
8. Lotus Pharmaceuticals, Inc. Implements Environmentally-friendly Cost Saving Strategies
9. Lotus Blossom Consulting Announces E-Book on Infertility Treatment Financing
10. Jazz Pharmaceuticals to Present at Investor Conferences
11. Rib-X Pharmaceuticals, Inc. to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... Qualidigm , the ... headquarters to a new, more expansive office space in order to accommodate its ... a distressed office building in Wethersfield, Conn. located at 936 Silas Deane Highway ...
(Date:3/28/2017)... ... March 28, 2017 , ... The Executives, Staff & ... money to for the Toys for Tots Literacy Campaign at their Semi-Annual Graduation and ... of $70 billion, the U.S. ranks at number 14 internationally in literacy. Statistically, a ...
(Date:3/28/2017)... ... , ... Public relations pros work hard to earn placements and build ... many results are clear, much of PR is hard to quantify. Goal-setting and measurement ... measurement, firms should always take an all-inclusive approach that takes both traditional and non-traditional ...
(Date:3/28/2017)... ... March 28, 2017 , ... Thank you to all who attended ... , This event was exclusive to providers and offered an opportunity to collaborate ... place at the Manchester Grand Hyatt where attendees gathered for a lively discussion on ...
(Date:3/27/2017)... ... March 27, 2017 , ... The respected ... who want straight teeth without the extensive time commitment and aesthetic disadvantages of ... acquiring a referral. A custom-designed series of virtually invisible aligners are created for ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... TEL-AVIV, Israel , March 27, 2017 /PRNewswire/ ... TASE: THXBY), a specialty clinical-stage pharmaceutical company specializing in the ... of its public offering in the ... Shares (ADSs), each ADS representing 40 ordinary shares ... per ADS. In addition, Therapix has granted the ...
(Date:3/27/2017)... LightIntegra Technology Inc. today announced that its ... President and Chief Executive Officer effective March 13, 2017. ... Directors of LightIntegra. Paul Geyer will continue ... "This is the perfect time for Bill ... We,ve selected a very strong leader at a time ...
(Date:3/27/2017)...  A new survey from the American ... Bidding Program (CBP) significantly reduced beneficiary choice and access ... choice forces beneficiaries to switch to unfamiliar or unsuitable ... AADE,s survey is the latest in a ... out the inherent problems with the CBP. Last year, ...
Breaking Medicine Technology: